Iovance Reports New Clinical Data for TIL Therapy in Soft Tissue Sarcoma

Iovance Biotherapeutics announced new clinical results for its tumor-infiltrating lymphocyte (TIL) therapy Lifileucel in patients with soft tissue sarcoma, highlighting the potential expansion of TIL therapy beyond melanoma.

Photo by CDC on Unsplash

Early Trial Results Show Promising Response Rates

In February 2026, the company released early findings from a clinical study evaluating lifileucel in patients with advanced soft tissue sarcoma who had previously received multiple lines of treatment.

Preliminary data from evaluable patients showed:

1. Objective response rate (ORR) of approximately 50%

2. Most participants had advanced or heavily pretreated disease

3. The therapy demonstrated a manageable safety profile consistent with prior studies

These results suggest that TIL therapy could offer a potential new treatment option for patients with difficult-to-treat solid tumors.

Photo by Mufid Majnun on Unsplash

Expanding TIL Therapy Beyond Melanoma

Lifileucel became the first TIL-based therapy approved for solid tumors when it received regulatory clearance for advanced melanoma under the brand name Amtagvi. The therapy works by isolating immune cells that have naturally infiltrated a patient’s tumor, expanding them in the laboratory, and reinfusing them into the patient to strengthen the anti-tumor immune response.

The new data indicate that the same approach may also be effective in other cancers, including sarcoma. According to the company, discussions with regulators are ongoing, and a registrational trial may begin in 2026 if results continue to show clinical benefit.

Photo by Jan Kopřiva on Unsplash

Growing Momentum for TIL-Based Cell Therapies

The development reflects broader momentum in the cell therapy field as researchers explore new approaches for treating solid tumors—an area where traditional CAR-T therapies have faced challenges.

Industry analysts note that expanding TIL therapy into additional tumor types could significantly increase the potential patient population and accelerate commercial adoption of this personalized immunotherapy approach.

Source: GlobeNewswire – Company announcement from Iovance Biotherapeutics regarding clinical results of lifileucel in soft tissue sarcoma (February 2026).